Positive Outcomes of High Hemoglobin Target in Patients With Chronic Kidney Disease Not on Dialysis: A Randomized Controlled Study

摘要: Correcting anemia in patients with chronic kidney disease (CKD) to higher hemoglobin (Hb) levels may be associated increased risk. No optimal target for Hb has been established. This controlled study examined 321 CKD who were not on dialysis, had a level of <10g/dL, and serum creatinine 2.0 6.0mg/dL. They randomized into two groups: 161 high (11.0-13.0g/dL) receive darbepoetin alfa low 160 (9.0-11.0g/dL) recombinant erythropoietin. The lasted 48weeks. Of 154 153 adverse events, cardiovascular events developed 42 51 the groups, respectively, no significant difference incidence. All quality life scores improved group vitality significantly more (P=0.025). left ventricular mass index (LVMI) remained stable group, but there was decrease LVMI (P<0.001). There safety concerns targeting during 48weeks this study. Patients comparatively better outcomes respect LVMI.